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Abstract
Background: Circulating endothelial microparticles (EMP) reflect the condition of the endothelium and are of increasing
interest in cardiovascular and inflammatory diseases. Recently, increased numbers of EMP following oral fat intake, possibly
due to acute endothelial injury, have been reported. On the other hand, the direct interference of lipids with the detection
of EMP has been suggested. This study aimed to investigate the effect of lipid-rich solutions, commonly administered in
clinical practice, on the detection, both in vitro and in vivo, of EMP.
Methods: For the in vitro assessment, several lipid-rich solutions were added to whole blood of healthy subjects (n=8) and
patientswith coronary heart disease (n=5). EMP (CD31+/CD42b2) were detected in platelet poor plasma by flow cytometry. For
the in vivo study, healthy volunteers were evaluated on 3 different study-days: baseline evaluation, following lipid infusion and
after a NaCl infusion. EMP quantification, lipid measurements and peripheral arterial tonometry were performed on each day.
Results: Both in vitro addition and in vivo administration of lipids significantly decreased EMP (from 198.6 to 53.0 and from
272.6 to 90.6/ml PPP, respectively, p=0.001 and p=0.012). The EMP number correlated inversely with the concentration of
triglycerides, both in vitro and in vivo (r=20.707 and 20.589, p,0.001 and p=0.021, respectively). The validity of EMP as a
marker of endothelial function is supported by their inverse relationship with the reactive hyperemia index (r=20.758,
p=0.011). This inverse relation was confounded by the intravenous administration of lipids.
Conclusion: The confounding effect of high circulating levels of lipids, commonly found in patients that receive intravenous
lipid-based solutions, should be taken into account when flow cytometry is used to quantify EMP.
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Introduction
Circulating endothelial microparticles (EMP) are increasingly
studied as markers of endothelial function in cardiovascular and
inflammatory diseases [1]. EMP are shed into the peripheral
circulation upon endothelial cell activation, apoptosis and injury,
and are therefore suited to reflect endothelial damage. Besides being
markers of endothelial function, EMP may have important functional
properties [2]. As such their modulating role in inflammation,
vascularfunctionand coagulationisincreasinglyrecognized [2].Flow
cytometry ismost oftenapplied to detectand quantify EMP [3]. Since
EMP precipitation may cause loss of microparticles (MP), measure-
ments are mainly performed directly in plasma [4].
In many critically ill patients, dysfunction of the endothelium is
an important factor, contributing to disease severity and
progression. Hence, there is growing interest in the evaluation of
the endothelial function in these patients using both in vivo
measurements and circulating markers, including microparticles
[5,6,7]. This group of patients also frequently receives lipid
solutions, either as a component of total parenteral nutrition
(TPN) or as part of the unique formulation of the sedative agent
propofol, resulting in a high prevalence of hyperlipidemia [8,9].
Lipemic plasma is well known to interfere with various
laboratory techniques, especially with those methods that use
light transmission as a detection manner. With regard to flow
cytometry lipemia, and particularly chylomicrons, impede platelet
detection [10]. In addition, several recent reports have shown
higher numbers of circulating EMP after a high fat meal, a finding
that was interpreted to reflect acute endothelial dysfunction
[11,12,13]. However, the direct influence of lipids on the flow
cytometric detection of EMP has not yet been investigated.
The aim of the present study was to assess the effect of a lipid-
rich solution on EMP quantification by flow cytometry, both in
vitro and in vivo. First, a pure lipid solution, TPN or propofol (the
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31496last two also contain high amounts of lipids) were added in vitro to
whole blood from healthy subjects and patients with coronary
heart disease. Second, we administered a parenteral lipid emulsion
to healthy individuals and determined the effects on the numbers
of EMP and in vivo endothelial function.
Results
In vitro study
Results are shown in table 1. All healthy volunteers (n=8) had
baseline fasting triglyceride (TG) concentrations below 150 mg/dl.
In the group of cardiovascular patients (n=5) the triglyceride
concentration was 133.3 mg/dl (58.5–155.8). In both study-
populations separately and grouped the addition of lipid-rich
solutions resulted in a significant increase of TG concentration
(p,0.05, in all 3 situations). A lower number of EMP was detected
by flow cytometry after the addition of lipids in all study subjects
(Figure 1). This decrease was significant in the two groups apart
and taken together (p,0.05, in all 3 situations) (Table 1). A non-
linear relation exists between the number of EMP and the TG
concentration in plasma (taken all in vitro data together,
r=20.707, p,0.001) (Figure 2).
In vivo study
Results are shown in Table 2. The in vivo infusion of a pure
lipid solution caused an increase in both plasma TG concentration
and chylomicron fraction (p=0.015 and 0.018, respectively).
There was also a trend towards a higher very low-density
lipoprotein (VLDL) fraction after lipid infusion, although not
statistically significant (p=0.074). No differences were found in the
total cholesterol concentration, high-density lipoprotein (HDL)
fraction or low-density lipoprotein (LDL) fraction. A lower number
of EMP was detected in all healthy volunteers after intravenous
administration of the lipid emulsion (day C, p=0.012), i.e. in
accordance with the in vitro data (Figure 3). There was no
statistically significant difference in reactive hyperemia index
(RHI) when measured on the various study-days.
Figure 1. Decrease in EMP after in vitro administration of lipid-
rich solutions. Whole blood was taken from 8 healthy volunteers
(black) and 5 patients with coronary heart disease (red). PPP was
prepared from different aliquots to which lipid-rich solutions were
added in different concentrations. EMP were detected by flow
cytometry as particles ,1 mm and CD31+/CD42b2. The figure shows
EMP numbers/ml PPP from samples without lipid-rich solutions (PPP),
and samples with added lipid-rich solutions in the lowest concentration
(Lipid). The number of EMP detected by flow cytometry decreased
significantly (all data taken together p=0.001). EMP=endothelial
microparticles, PPP=platelet poor plasma.
doi:10.1371/journal.pone.0031496.g001
Figure 2. The inverse relation between EMP and TG after the in
vitro administration of lipid-rich solutions to whole blood.
Whole blood was taken from 8 healthy volunteers (black) and 5 patients
with coronary heart disease (red). PPP was prepared from different
aliquots to which lipid-rich solutions were added in different
concentrations. EMP were detected by flow cytometry as particles
,1 mm and CD31+/CD42b2, and TG concentration were determined in
plasma. The figure shows EMP numbers/ml PPP from samples without
lipid-rich solutions (black inversed triangles for the healthy volunteers
and red diamonds for the cardiovascular patients) and samples with
added lipid-rich solutions in different concentrations (black quadrangles
for the healthy volunteers and red triangles for the cardiovascular
patients). Taken all samples together a non-linear inverse relation exists
between TG concentration and the number of EMP (r=20.707,
p,0.001). EMP=endothelial microparticles, PPP=platelet poor plasma,
TG=triglycerides.
doi:10.1371/journal.pone.0031496.g002
Table 1. In vitro study results.
Healthy controls (N=8) Cardiovascular patients (N=5) Total (N=13)
TG in PPP (mg/dl) 98.0 (69.9–138.4) 133.3 (58.5–155.8) 108.4 (58.5–155.8)
TG in lipid sample (mg/dl)* 325.5 (201.4–617.7)
$ 225.7 (208.5–248.9)
1 289.4 (201.4–617.7)
**
EMP in PPP (/ml PPP) 253.4 (93.9–347.6) 197.2 (63.6–407.3) 198.6 (63.6–407.3)
EMP in lipid sample (/ml PPP)* 55.4 (30.1–152.5)
$ 45.2 (17.9–88.9)
1 53.0 (17.9–152.5)
**
*For every volunteer/patient the sample with the lowest amount of lipid-rich solutions added was used.
$Compared to PPP Wilcoxon signed rank test, p=0.012.
1Compared to PPP Wilcoxon signed rank test, p=0.043.
**Compared to PPP Wilcoxon signed rank test, p=0.001.
Whole blood was taken from 8 healthy volunteers and 5 patients with coronary heart disease. PPP was prepared from different aliquots to which lipid-rich solutions
were added in different concentrations. EMP were detected by flow cytometry as particles ,1 mm and CD31+/CD42b2, and TG concentration were determined in
plasma. EMP=endothelial microparticles, TG=triglycerides, PPP=platelet poor plasma.
doi:10.1371/journal.pone.0031496.t001
Lipids and Flow Cytometric EMP Detection
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31496The in vivo study showed an inverse relation between the TG
concentration and EMP numbers (r=20.589, p=0.021), as well
(Figure 4). A similar inverse relation was found between EMP
numbers, the chylomicron fraction and the VLDL fraction
(r=20.700 and r=20.545, p=0.004 and 0.036, respectively).
Combined results obtained on day A and B, showed an inverse
linear relation between EMP and RHI (r=20.758, p=0.011)
(Figure 5). This inverse relationship was confounded when all data
were taken into account, i.e. including those after intravenous lipid
infusion (r=20.254, p=0.361 combining all data) (Figure 5).
Discussion
We investigated the effects of lipid-rich solutions on the flow
cytometric detection of plasma EMP, both in vitro and in vivo.
Several findings emerged from this study. First, both in vitro and
in vivo administration of lipid-rich solutions lowered the number
of EMP detected by flow cytometry in healthy volunteers. The in
vitro effect was further confirmed in a group of 5 patients with
Figure 3. Evolution of EMP detected by flow cytometry in the
in vivo study. 5 healthy volunteers were evaluated on 3 different
study days (all 5 represented in a different color and symbol). Day A:
blood was collected after an overnight fast. EMP were detected by flow
cytometry as particles ,1 mm and CD31+/CD42b2 in PPP. Day B: NaCl
0.9% was administered in fasting conditions and the same measure-
ments as on day A were performed. Day C: the same protocol was used
as on day B, but a pure lipid solution was infused instead of NaCl. A
lower number of EMP was detected in all healthy volunteers after
intravenous administration of the lipid emulsion (p=0.012). EMP=en-
dothelial microparticles, PPP=platelet poor plasma.
doi:10.1371/journal.pone.0031496.g003
Table 2. In vivo study: results for the different study-days.
Day A Day B Day C
TG (mg/dl) 87.5 (70.0–131.5) 68.9 (59.5–118.1) 202.2 (149.5–278.9)*
CH (mg/dl) 184.5 (170.3–188.5) 190.0 (176.9–198.9) 185.2 (169.2–192.1)
LDL (%) 53.6 (46.8–61.9) 51.1 (46.7–61.7) 48.5 (43.4–58.5)
HDL (%) 42.0 (31.6–44.2) 43.6 (31.6–46.5) 36.2 (26.3–46.2)
VLDL (%) 7.0 (4.5–9.1) 5.0 (4.6–6.2) 9.1 (5.4–11.0)
Chyl (%) 1.3 (1.2–1.4) 0.0 (0.0–2.2) 4.3 (4.1–7.5)*
EMP/ml PPP 272.6 (128.6–405.6) 187.3 (108.6–379.1) 90.6 (15.2–124.6)*
RHI 1.60 (1.46–2.1) 1.90 (1.07–2.65) 1.38 (1.34–2.55)
Results are expressed as median (min-max).
*Friedman test p,0.05 and Wilcoxon signed rank test Day C vs. Day B and Day
C vs. Day A p,0.05.
5 healthy volunteers were evaluated on 3 different study days. Day A: blood
was collected after an overnight fast and PAT was performed. EMP were
detected by flow cytometry as particles ,1 mm and CD31+/CD42b2 in PPP.
Day B: a NaCl 0.9% infusion was administered in fasting conditions and the
same measurements as on day A were performed. Day C: the same protocol
was used as on day B, but a pure lipid solution was infused instead of NaCl.
CH=cholesterol, chyl=chylomicrons, EMP=endothelial microparticles,
HDL=High density lipoproteins, LDL=low density lipoproteins,
PAT=peripheral arterial tonometry, RHI=reactive hyperemia index,
TG=triglycerides, VLDL=very low density lipoproteins.
doi:10.1371/journal.pone.0031496.t002
Figure 4. In vivo there is a non-linear inverse relation between
TG concentration and EMP detected in plasma. 5 healthy
volunteers were evaluated on 3 different study days. Day A: blood
was collected after an overnight fast. EMP were detected by flow
cytometry as particles ,1 mm and CD31+/CD42b2 in PPP, and lipid
profile was determined on frozen plasma samples. (Black dots) Day B:
NaCl 0.9% was administered in fasting conditions and the same
measurements as on day A were performed. (Black open triangles) Day
C: the same protocol was used as on day B, but a pure lipid solution was
infused instead of NaCl. (Gray diamonds) There is an inverse non-linear
relation between the TG concentration in plasma and the number of
EMP number/ml PPP detected (r=20.589, p=0.021). EMP=endothelial
microparticles, PPP=platelet poor plasma, TG=triglycerides.
doi:10.1371/journal.pone.0031496.g004
Figure 5. In healthy volunteers the inverse relation of EMP with
RHI is confounded by the intravenous administration of a pure
lipid solution. 5 healthy volunteers were evaluated on 3 different
study days. Day A: blood was collected after an overnight fast and PAT
was performed. EMP were detected by flow cytometry as particles
,1 mm and CD31+/CD42b2 in PPP. Day B: a NaCl 0.9% infusion was
administered in fasting conditions and the same measurements as on
day A were performed. Day C: the same protocol was used as on day B,
but a parenteral lipid emulsion was infused instead of NaCl. On day A
and B (black dots) there was an inverse relation between EMP numbers/
ml PPP and RHI (r=20.758, p=0.011 combining data from day A and
day B). This relation was confounded by lipid infusion as on day C (gray
quadrangles) (r=20.254, p=0.361 combining all data). EMP=endothe-
lial microparticles, PAT=peripheral arterial tonometry, PPP=platelet
poor plasma, RHI=reactive hyperemia index.
doi:10.1371/journal.pone.0031496.g005
Lipids and Flow Cytometric EMP Detection
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inversely to plasma TG concentrations. Last, there was a negative
correlation between baseline EMP numbers and RHI, obtained
with peripheral arterial tonometry (PAT). This finding underscores
the value of EMP as markers of endothelial function.
The endothelium plays a key role in the regulation of vascular
tone, barrier function, coagulation, inflammation and angiogenesis
[14]. Circulating factors, such as EMP, in addition to the in vivo
assessment of endothelial function, are increasingly used to
evaluate endothelial damage. EMP express membrane proteins,
which are related to their endothelial origin, but also depend on
the process that causes their release [15]. For example, apoptosis
of endothelial cells increases the numbers of circulating CD31+/
CD42b2 EMP. Besides the fact that EMP reflect the ‘‘general
condition’’ of the endothelium, there is a growing awareness that
these particles may act as small vectors, transporting proteins,
lipids, DNA, RNA and miRNA, through which they modulate
inflammation, vascular function and coagulation [2].
Lipids and endothelial function
The effect of lipids on EMP measurements was mostly studied
after the administration of a lipid-rich meal [11,12,13,16].
Generally, a higher circulating number of postprandial EMP
was found in these studies. These data have been interpreted as the
result of postprandial endothelial damage, involving hypertriglyc-
eridemia, hyperglycemia and hyperinsulinemia [17,18]. In most
studies TG concentrations obtained after a lipid-rich meal, were
lower than the values achieved in the present study. As illustrated
in figure 2 and 4, the non-linear relation between EMP and TG
suggests that there might be a certain threshold, above which
interference with EMP quantification becomes significant after the
addition of lipid-rich solutions.
The lipid-rich solutions that were used in the present study,
obviously differ from the physiological nutritional and hormonal
situation obtained after a high fat meal [19]. The lipid composition
of intralipid is fixed (1.2% phospholipids, 20% TG containing
predominantly unsaturated fatty acids and 2.25% glycerin), while
the lipid composition (saturated, unsaturated fatty acids and
cholesterol) of high fat meals differs between studies. We
intravenously administered low doses of fat (12 g or 6 g/h) in
the form of chylomicron-like particles, without the administration
of carbohydrates or proteins. As such there are quantitative and
qualitative differences with regard to chylomicrons and chylomi-
cron-like lipid particles post-intravenous lipid administration,
compared to the situation after a lipid-rich meal. Although we
cannot exclude that the latter may also have affected endothelial
function, further elucidation of this possible interaction was
beyond the scope of our study.
The possible influence of an intravenously administered pure
lipid solution on the detection of EMP has never been reported
until now. With regard to the effect of exogenous lipid
administration on in vivo endothelium-dependent vasodilation,
conflicting results have been described [20,21]. In the present
study we found a decreased number of CD31+/CD42b2 EMP,
and no difference in RHI.
Lipids and flow cytometry for EMP
A significant number of pre-analytical and analytical variables
has been described, all of which appear to confound exact EMP
quantification [22]. Within the International Society of Throm-
bosis and Haemostasis, great effort has been put into standard-
ization of the pre-analytical and analytical issues, but a widely
adopted protocol is still lacking. Storage time of whole blood and
plasma, and centrifugation speed are known to influence MP
measurement, all of which were controlled in this particular study.
Since microparticles are measured mostly directly in PPP, it is
possible that other components present in plasma, such as lipids,
interfere with EMP detection. Several reports describe elevated
EMP numbers after a high fat meal, a phenomenon that is
considered to reflect acute endothelial dysfunction [17,18].
However, data on the possible interference of lipids with the flow
cytometric quantification of EMP are scarce.
In lipemic plasma, chylomicrons and VLDL cause light
scattering and lead to turbidity and cloudiness [19]. The size of
microparticles is in the range of chylomicrons, VLDL and artificial
lipid particles. Previous studies showed that chylomicrons appear
in the forward (FSC) and side scatter (SSC) region of interest for
microparticle analysis, and can interfere with MP detection [23].
Chylomicrons, VLDL and artificial lipid particles are present in
plasma during the administration of a pure lipid solution, and
might therefore at least partly explain the current findings. Besides
interference by light scattering; antigen-antibody-binding and
interactions in the pre-analytical methods, e.g. upon centrifuga-
tion, can also occur. Further investigation on the mechanisms
underlying this interference is advocated.
To avoid interference with microparticle analyses in lipid-rich
plasma samples, Shet et al suggested that the upper lipid layer is to
be avoided during pipetting [3]. In our hands the lipids are not
always clearly delineated, so avoiding them canbe difficult. Another
possible solution is the isolation of MP from plasma by high speed
centrifugation, as applied by Sustar et al [16]. Since lipids shift
upwardsinplasmaduringcentrifugation,itislikelythatthemajority
will be removed with the supernatants, thereby avoiding interfer-
ence with flow cytometric detection [24]. High-speed centrifugation
(13 000 g for 45 minutes) of plasma diluted with buffer allows the
removalofthe plasma containinglipids.Nevertheless,notallplasma
microparticles will be sedimented by high speed centrifugation [4].
Despite diluting plasma in buffer to decrease the density, we could
only spin down around two third of the EMP (own data not shown).
Furthermore, since the sedimentation of microparticles depends on
thedensityoftheplasma,wedonotexactlyknow whattheinfluence
of the additional lipids will be on the sedimentation rate.
The limited number of volunteers evaluated in the in vivo part of
this study, could explain the lack of a statistically significant
difference in terms of endothelial function following the administra-
tion of a pure lipid solution. However, our results clearly show that
the inverse relation between EMP numbers and endothelial function
is confounded after lipid infusion. (Figure 5) This observation
suggeststhatlowerEMPnumbersareatechnicalartifactattributable
to interference of lipids. Furthermore, in vitro and in vivo data point
into the same direction, and show a uniform lipid-induced reduction
in EMP numbers in all volunteers. (Figure 1 and 3)
Our findings may have practical implications for future
research. Besides the determination of EMP as a surrogate marker
for endothelial function in cardiovascular diseases, it is also
increasingly used in critically ill [2,5]. The latter group is
frequently exposed to intravenous lipid administration, as most
sedated patients receive high amounts of propofol formulated as a
lipid emulsion. Furthermore, many sick patients both in and
outside the ICU also receive TPN, a solution rich in lipids. Both
treatments lead to a significant elevation of TG levels, which are
well in the range of those observed in our healthy volunteers [8,9].
In those patients in particular, the interference of high lipid levels
on EMP numbers should be taken into account.
Conclusion
While the relation between EMP, as a marker of endothelial
function, and lipidemia is an important topic in the current
Lipids and Flow Cytometric EMP Detection
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plasma on the flow cytometric detection of EMP. We observed that,
both in vitro and in vivo, lipid-rich solutions lower the numbers of
EMP detected by flow cytometry in healthy volunteers and
cardiovascular patients. This decrease is inversely and non-linearly
related to the concentration of TG in plasma. The inverse
relationship between EMP and RHI, underscores the valid use of
EMP as a marker of endothelial function. However, this inverse
relation is disturbed by the presence of high lipid levels. This
strongly suggests that in lipemic samples, the interpretation of EMP
measurements by flow cytometry needs to be executed with caution.
Materials and Methods
The study protocol was approved by the research and ethics
committee of the Antwerp University Hospital, corresponding to the
principles outlined inthe Declaration ofHelsinki(B30020108323). A
written informed consent was obtained from all subjects.
In vitro study
Blood was sampled from 8 healthy volunteers (median [min-
max] age 30 [26–49] years, 7 females, no cardiovascular risk
factors), after an overnight fast. Furthermore 5 patients with
known coronary heart disease were included (characteristics in
Table 3). One had coronary vasospasms and the 4 others had
coronary atheromatosis. Blood sampling procedure was performed
using ACD vacutainer tubes (BD diagnostics, Erembodegem
Belgium) as previously described [22]. Lipid-rich solutions were
added to different aliquots of whole blood: propofol 1%
(DiprivanH, AstraZeneca) 1.2 ml/ml, 2.4 ml/ml or 4.8 ml/ml (i.e.
0.12, 0.24 and 0.48 mg lipids added/ml whole blood, respectively)
(n=2), TPN containing SMOFlipidH (Fresenius Kabi) 35 ul/ml
and 70 ml/ml (n=1) (i.e. 1.16 and 2.33 mg lipids added/ml blood,
respectively), a pure lipid solution (IntralipidH 20%, Fresenius
Kabi) 2.5 ml/ml (i.e. 0.5 mg lipids added/ml whole blood) (n=4)
or 5 ml/ml (i.e. 1 mg lipids added/ml whole blood) (n=1). The
amount of lipid-rich solutions added to the plasma was chosen to
achieve conditions comparable to those obtained after the in vivo
administration of TPN or propofol in patients. In short, all samples
were mixed gently at room temperature for 15 minutes, then PPP
was prepared by two 20 minute centrifugations at 1550 g without
acceleration or break. The samples with and without the addition
of lipid-rich solutions were all processed in the same manner. Since
the amount of circulating EMP in the plasma of healthy volunteers
is low, we chose the most robust marker for EMP detection, i.e.
CD31+/CD42b2 [1,22]. For the detection of EMP, PPP was
incubated at 4uC for 20 minutes with CD31-PE (BD Biosciences,
Erembodegem Belgium) and CD42b-FITC (BD Bioscience,
Erembodegem Belgium), both 0.22 mm filtered and azide free.
Samples were diluted in 0.22 mm filtered FACSflow (BD
Biosciences, Erembodegem Belgium), to allow sample acquisition
at less than 1000 events/sec on low flow rate. Samples were
analyzed on a FACSCantoII (BD Biosciences, Erembodegem
Belgium). The upper detection limit of our microparticle gate on
FSC and SSC was established using Fluoresbrite YG 1 mm
calibration size beads (Polysciences, Eppelheim Germany).
(Figure 6) The lower detection limit, a FSC and SSC threshold,
was placed above the electronic noise of our cytometer; this
corresponds with the upper boarder of 0.5 mm beads on FSC.
(Figure 6) The position of the peak signal of the 1 mm beads on
FSC and SSC was maintained at the same place. Background
noise in 0.22 mm filtered FACS flow was checked daily so that it
was less than 100 events/sec. Trucount tubes (BD Biosciences,
Erembodegem Belgium) were run in parallel to determine final
MP concentration per ml PPP. EMP were defined as particles
smaller than 1 mm that were CD31-positive and CD42b-negative
[22].(Figure 7) Antibodies were titrated, and isotype fluorescence-
minus-one and unstained samples were run as controls. All
samples were measured in duplicate. Mean coefficient of variation
was 6.84% for PPP and 10.11% for lipid-rich PPP. Antibody
binding specificity was verified in lipid-poor and lipid-rich samples
by a competition assay using excess (10 times) of unconjugated
CD31 and CD42b antibody (BD Biosciences, Erembodegem
Belgium), after titration (Data not shown). The pure lipid emulsion
in buffer (0.22 mm filtered FACSflow) caused a typical scatter
pattern on FSC-SSC, which we could retrieve in our lipid-rich
plasma samples, and was not autofluorescent (Data not shown).
All plasma samples, both PPP without and with added lipid-rich
solutions, were analyzed for triglyceride (TG) concentration using
Vitros Ortho Clinical Diagnostics (Johnson & Johnson).
In vivo study
5 healthy volunteers (median [min-max] age 27 [26–30] years; 3
females; no cardiovascular risk factors) were evaluated on 3
different study-days, applied in random order. On day A, blood
was collected after an overnight fast. PPP was prepared
immediately for EMP detection and plasma samples were frozen
at 280uC for lipid measurements. In vivo assessment of
endothelial function was performed (see further) after 30 minutes.
On day B, fasting volunteers received a NaCl 0.9% infusion (0.5 or
1 ml/min) during 1 hour, after which the same laboratory and
clinical measurements were performed as on day A. The infusion
continued during these measurements. Day C was similar to day
B, but a parenteral pure lipid emulsion (IntralipidH 20%,
AstraZeneca) (0.5 or 1 ml/min) was infused instead of NaCl
0.9%. Two different infusion speeds were chosen to obtain
different triglyceride concentrations.
For the infusion, a peripheral catheter was placed in the dominant
arm. Blood was collected from the non-dominant arm. EMP were
detected in fresh PPP using flow cytometry as described above. All
samples were run in duplicate. Mean coefficient of variation for Day
A, B and C was 4.21, 7.38 and 11.37%, respectively.
The lipid profile was determined on plasma samples frozen at
280uC using Dimension Vista 1500 Systems (Siemens). The
lipoprotein composition was evaluated using zone electrophoresis
Table 3. Characteristics of cardiovascular patients (n=5).
Age years (median
[min-max])
59 (50–65) Coronarography
results
Gender (F/M) 1/4 Significant stenosis3
Body mass index
median [min-max])
24.0 (22.7–31.6) Non significant stenosis 1
Cholesterol mg/dl
(median [min-max])
137 (117–211) Treatment
Cardiovascular (CV)
risk factors
ACE-inhibitor or sartan 4
-Familial history of CV disease 3 b-Blocker 2
-Smoking (active) 3( 1 ) Acetylsalicylic acid 5
-Arterial hypertension 4 Statin 3
-Hypercholesterolemia 4
-Diabetes (insulin dependent) 2( 1 )
CV disease=cardiovascular disease.
doi:10.1371/journal.pone.0031496.t003
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e31496Figure 6. Gating strategy microparticle dimension criteria. Fluoresbrite YG 1 mm calibration size beads (Polysciences, Eppelheim Germany)
were used to set forward (FSC) and side scatter (SSC) criteria for the assessment of microparticles. Beads were measured at low flow rate and
threshold was placed on both FSC and SSC. More in particular, the MP analysis region was defined as follows: at first, the bead population was
selected on a histogram of the FSC signal (A), while the events within this gate were further selected on SSC signal (B); the upper detection limit of
the microparticle gate was set on the peak of the selected 1 mm beads on histogram plots of FSC (C) and SSC (D). For illustrative purposes, the
population hierarchy is shown in figure E. The lower dimension criterion was set just above the electronic noise of the cytometer, which
corresponded with the upper boarder of the Fluoresbrite YG 0.5 mm calibration size beads on FSC as illustrated in figures F and G. In figure F, the
threshold was placed on FITC, and in figure G, the threshold was placed on FSC and SSC. As an illustration our microparticle dimension criteria are
shown as a rectangular gate in figure F and G. The position of the peak signal of the 1 mm beads on FSC and SSC was maintained at the same place
by adjusting the FSC and SSC voltage when necessary. FITC=fluorescein, FSC-H=forwards scatter height, SSC-H=sight scatter height,
MP=microparticles, PPP=platelet poor plasma.
doi:10.1371/journal.pone.0031496.g006
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percentage of the total lipoprotein content.
For the in vivo assessment of endothelial function, peripheral
arterial tonometry (PAT), endoPATH (Itamar, Israel) was used in
accordance to the guidelines published by the European Society of
Cardiology [25]. Subjects were analyzed in a quiet room after
acclimatization, and at least 30 minutes after the blood collection.
Suprasystolic occlusion of the non-dominant upper arm, at
200 mmHg or 60 mmHg above systolic blood pressure, was
obtained using a cuff. The reactive hyperemia index (RHI) was
calculated with the Itamar software (version 3.2.4).
Statistics
The statistical program SPSS version 18 was used for data
analysis. Due to the limited sample size, non-parametric tests were
used. Data are expressed as median (min-max). Wilcoxon signed
rank test was used to compare groups in the in vitro study. To
compare the 3 different study-days in the in vivo study, the
Friedman test was applied and if significant, a Wilcoxon signed
rank test was performed comparing the different study-days two by
two. Spearman correlation coefficient was used to evaluate the
relation between TG lipid profile, EMP number and PAT
measurements.
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Figure 7. Microparticle gating strategy. For the detection of EMP, PPP was incubated at 4uC for 20 minutes with CD31-PE (BD Biosciences,
Erembodegem Belgium) and CD42b-FITC (BD Bioscience, Erembodegem Belgium), both 0.22 mm filtered and azide free. Samples were diluted in
0.22 mm filtered FACSflow (BD Biosciences, Erembodegem Belgium), to allow sample acquisition at less than 1000 events/sec on low flow rate.
Samples were analyzed on a FACSCantoII (BD Biosciences, Erembodegem Belgium). Antibodies were titrated, and isotype fluorescence-minus-one for
FITC (C) and PE (D) and unstained samples (A) were run as controls. EMP were defined as particles smaller than 1 mm that were CD31-positive and
CD42b-negative (B). For illustrative reasons the MP gate is shown as a rectangular gate. For the settings of the dimension criteria see figure 6.
EMP=endothelial microparticle, FITC=fluorescein, FSC-H=forwards scatter height, SSC-H=sight scatter height, MP=microparticle, PE=phycoer-
ythrin, PPP=platelet poor plasma.
doi:10.1371/journal.pone.0031496.g007
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